PietroRavani CanadaUniversity of Calgary

Dr. Pietro Ravani is a Professor and Clinician Scientist in the Department of Medicine and Institute of Public Health at the University of Calgary. Dr. Ravani received his medical training at the University of Parma, Italy, and completed a Master’s of Science in Biostatistics at the University of Pavia, Italy, followed by a PhD in Clinical Epidemiology at Memorial University in Newfoundland. Dr. Ravani worked as a practicing physician in Italy until 2008, when he moved to Calgary. His research interests include statistical methods in outcomes research and design of clinical trials and longitudinal studies in kidney disease.

Institution

Day 2 - Monday April 15, 2024

Time	Session

9 a.m. 10:30 a.m.	Insights From Understanding Heterogeneous Trajectories to Kidney Failure LF03 FacundoDaminato Chairperson fmdaminato@hotmail.comArgentina Magdalena Madero Chairperson MexicoChief of Nephrology, Instituto Nacional de Cardiol PietroRavani Chairperson pravani@ucalgary.caCanadaUniversity of Calgary Non-neoplastic Lesions in Nephrectomy Samples: Implications for Kidney Function JairMunoz Mendoza Speaker JMMendoza@med.miami.eduUnited StatesUniversity of Miami Understanding the Heterogeneous Trajectory of CKD MorganGrams Speaker morgan.grams@nyulangone.orgUnited StatesNew York University Review of Medical Therapies Proven to Delay CKD Progression DoreenZhu Speaker doreen.zhu@ndph.ox.ac.ukUnited KingdomUniversity of Oxford Impact of Obesity and Novel Treatment Strategies on CKD Progression PeterRossing Speaker DenmarkSteno Diabetes Center Copenhagen Q and A Hall C4
3 p.m. 4 p.m.	Late Breaking Clinical Trials Session LBCT AlessiaFornoni Chairperson United StatesUniversity of Miami MichelleRheault Chairperson rheau002@umn.eduUnited StatesUniversity of Minnesota Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict) PietroRavani Free Communication pravani@ucalgary.caCanadaUniversity of Calgary Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkDenmarkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research Consultant EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY DanaRizk Free Communication drizk@uabmc.eduUnited StatesUniversity of Alabama at Birmingham SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL JonathanBarratt Free Communication United KingdomUniversity of Leicester, Leicester, UK PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT CécileCouchoud Free Communication cecile.couchoud@biomedecine.frFranceREIN registry, Agence de la biomédecine, France Hall A